Acorda Therapeutics Inc. (ACOR)

25.80
NASDAQ : Health Technology
Prev Close 25.10
Day Low/High 25.35 / 26.65
52 Wk Low/High 13.60 / 33.00
Avg Volume 702.40K
Exchange NASDAQ
Shares Outstanding 46.75M
Market Cap 1.16B
EPS -4.90
P/E Ratio 14.34
Div & Yield N.A. (N.A)

Latest News

Acorda Fourth Quarter/Year End 2017 Update

Acorda Fourth Quarter/Year End 2017 Update

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates on Thursday, February 15 at 8:30 a.

Notable Thursday Option Activity: ACOR, VHC, TREE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acorda Therapeutics Inc , where a total volume of 4,420 contracts has been traded thus far today, a contract volume which is representative of approximately 442,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 74.2% of ACOR's average daily trading volume over the past month, of 595,775 shares.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Acorda Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acorda Therapeutics, Inc.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Notable Monday Option Activity: ACOR, MODN, SCHN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acorda Therapeutics Inc , where a total of 3,761 contracts have traded so far, representing approximately 376,100 underlying shares. That amounts to about 68% of ACOR's average daily trading volume over the past month of 552,810 shares.

Acorda Announces 2017 AMPYRA Net Sales And Provides 2018 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Announces 2017 AMPYRA Net Sales And Provides 2018 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166 million.

ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acorda Therapeutics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed Against Acorda Therapeutics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed Against Acorda Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Acorda Therapeutics, Inc.

Acorda Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Acorda Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Acorda Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline

Pomerantz LLP announces that a class action lawsuit has been filed against Acorda Therapeutics, Inc.

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

Jim Cramer highlights T-Mobile US, Take-Two Interactive, Activision Blizzard, Owens Corning and more.

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Weakness has been a clarion call to sell for so many, when it's really the buying opportunity that so few people recognize.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Acorda Therapeutics, Inc. Shareholders And A Lead Plaintiff Deadline Of January 17, 2018

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Acorda Therapeutics, Inc. Shareholders And A Lead Plaintiff Deadline Of January 17, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acorda Therapeutics, Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

ACOR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Acorda Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 17, 2018

ACOR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Acorda Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 17, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Acorda Therapeutics, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Acorda Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Acorda Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Acorda Therapeutics, Inc.

Acorda Resubmits New Drug Application For INBRIJA™ (CVT-301, Levodopa Inhalation Powder)

Acorda Resubmits New Drug Application For INBRIJA™ (CVT-301, Levodopa Inhalation Powder)

Acorda Therapeutics (Nasdaq:ACOR) announced the resubmission of its New Drug Application (NDA) for INBRIJA to the U.

The Klein Law Firm Announces The Commencement Of A Class Action Filed On Behalf Of Acorda Therapeutics, Inc. Shareholders And A Lead Plaintiff Deadline Of January 17, 2018

The Klein Law Firm Announces The Commencement Of A Class Action Filed On Behalf Of Acorda Therapeutics, Inc. Shareholders And A Lead Plaintiff Deadline Of January 17, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acorda Therapeutics, Inc.

ACOR INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Acorda Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 17, 2018

ACOR INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Acorda Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 17, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Acorda Therapeutics, Inc.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Acorda Therapeutics, Inc. Investors (ACOR)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Acorda Therapeutics, Inc. Investors (ACOR)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Acorda Therapeutics, Inc.

ACOR INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Acorda Therapeutics, Inc. Investors

ACOR INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Acorda Therapeutics, Inc. Investors

Law Offices of Howard G. Smith continues its investigation on behalf of Acorda Therapeutics, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acorda Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acorda Therapeutics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Acorda Therapeutics, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Acorda Therapeutics, Inc. (ACOR)

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Acorda Therapeutics, Inc. (ACOR)

The Klein Law Firm announces the commencement of an investigation of Acorda Therapeutics, Inc.

TheStreet Quant Rating: D+ (Sell)